Case Report

Rapid Evolution to Blast Crisis Associated with a Q252H *ABL1* Kinase Domain Mutation in e19a2 *BCR-ABL1* Chronic Myeloid Leukaemia

Sarah L. McCarron,¹ Karena Maher,² Johanna Kelly,³
Mary F. Ryan,² and Stephen E. Langabeer¹

¹ Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James's Hospital, Dublin 8, Ireland

² Department of Haematology, Waterford Regional Hospital, Waterford, Ireland

³ National Centre for Medical Genetics, Our Lady's Children's Hospital, Dublin 12, Ireland

Correspondence should be addressed to Stephen E. Langabeer; slangabeer@stjames.ie

Received 26 June 2013; Accepted 19 August 2013

Academic Editors: K. Nakase, N. Nara, A. Ohsaka, and T. Sonoki

Copyright © 2013 Sarah L. McCarron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A minority of chronic myeloid leukaemia (CML) patients express variant transcripts of which the e19a2 *BCR-ABL1* fusion is the most common. Instances of tyrosine kinase inhibitor (TKI) resistance in e19a2 *BCR-ABL1* CML patients have rarely been reported. A case of e19a2 *BCR-ABL1* CML is described in whom imatinib resistance, associated with a Q252H *ABL1* kinase domain mutation, became apparent soon after initiation of TKI therapy. The patient rapidly transformed to myeloid blast crisis (BC) with considerable bone marrow fibrosis and no significant molecular response to a second generation TKI. The clinical course was complicated by comorbidities with the patient rapidly succumbing to advanced disease. This scenario of Q252H-associated TKI resistance with rapid BC transformation has not been previously documented in e19a2 *BCR-ABL1* CML. This case highlights the considerable challenges remaining in the management of TKI-resistant BC CML, particularly in the elderly patient.

1. Introduction

The *BCR-ABL1* oncogene is the molecular hallmark and causative event of CML. Most CML patients express either e13a2 or e14a2 *BCR-ABL1* fusion transcripts, but approximately 5% of patients express variant transcripts that may involve fusion of alternative exons, insertions, or breakpoints within exons. Of these variant *BCR-ABL1* fusions, e19a2 is the most common. CML with e19a2 *BCR-ABL1*, that encodes a 230 kDa protein [1], was initially reported in neutrophilic CML with a relatively indolent clinical course [2] but has subsequently been reported in typical CML presenting in all phases [3–8].

Soon after the introduction of TKI therapy for CML, it became apparent that a significant proportion of patients are either primary refractory, display suboptimal responses, or acquire resistance to imatinib [9]. One of the most common causes of acquired resistance is the development

of mutations within the *BCR-ABL1* kinase domain (KD) that prohibit effective binding of imatinib [10]. Greater than ninety of these mutations have been reported in imatinib resistant CML patients, the effects of the majority of which may be overcome by imatinib dose escalation or a second generation TKI [11]. Very few *BCR-ABL1* KD mutations have been reported in e19a2 *BCR-ABL1* CML [12–15] making an informed choice of subsequent TKI or alternative therapeutic approach problematic in the context of this transcript type.

Despite evidence suggesting that fewer patients transform to accelerated and blast crisis (BC) phases when treated with long term imatinib [16], transformation still occurs in a minority of CML patients. Second generation TKIs, allogeneic haematopoietic stem cell transplantation, and investigational agents have been shown to be of benefit [17], yet the outlook remains poor for a significant number, particularly those elderly patients with significant comorbidities.

FIGURE 1: (a) qPCR of e19a2 *BCR-ABL1* transcripts over clinical course and (b) sequence of *ABL1* KD.

2. Case Report

A seventy-eight-year-old male presented with tiredness. He was noted to have raised white cell count and platelets on routine monitoring of his chronic disorders which included hypertension, ischemic heart disease, haemochromatosis, and intracranial aneurysm. A full blood count showed a white cell count $33.5 \times 10^9/L$, haemoglobin 13.4 g/dL, and platelets of $762 \times 10^9/L$. The white cell differential was comprised of neutrophils $19.8 \times 10^9/L$, myelocytes $2.0 \times 10^9/L$, metamyelocytes $2.0 \times 10^9/L$, lymphocytes $5.0 \times 10^9/L$, monocytes $1.3 \times 10^9/L$, eosinophils $0.3 \times 10^9/L$, and basophils $2.4 \times 10^9/L$. A bone marrow aspirate was hypercellular with significant myeloid and megakaryocytic hyperplasia with reduced erythroid series and no fibrosis evident. Cytogenetic analysis revealed 45,X,-Y,t(9; 22)(q34; q11.2) in 20/20 metaphases. A standard reverse-transcriptase polymerase chain reaction (PCR) methodology for detection of *BCR-ABL1* transcripts [18] showed a single band that upon sequencing demonstrated an e19a2 *BCR-ABL1* fusion leading to a diagnosis of chronic phase CML. The patient commenced on hydroxycarbamide 1 g/day then imatinib 400 mg od one week later. He achieved haematological remission within three months, but thrombocytopenia became rapidly evident prompting an increase in imatinib to 800 mg od. Again, his blood counts normalized, but this was not sustained. Peripheral blood quantitative PCR (qPCR) was performed as previously described [19] at four months and demonstrated no significant decrease in *BCR-ABL1* transcript levels (Figure 1(a)). This prompted investigation for an *ABL1* KD mutation [20]. Sequencing of the *ABL1* KD revealed a Q252H mutation (Figure 1(b)). As *ABL1* KD mutation bearing clones may exist in a minority of CML patients at presentation [21], retrospective analysis was performed but did not demonstrate the presence of the Q252H at presentation. The patient was switched to nilotinib 300 mg bd. At seven months he was deteriorating clinically with increasing splenomegaly and myeloblasts seen in the peripheral blood (white cell count $71.5 \times 10^9/L$, basophils $8.6 \times 10^9/L$, and myeloblasts $15.0 \times 10^9/L$) indicating myeloid

blast crisis. A further fragmented bone marrow biopsy demonstrated hypercellularity secondary to increased blast cell numbers (Figure 2(a)) with grade II fibrosis (Figure 2(b)). As the presence of a concurrent myeloproliferative neoplasm (MPN) could have been responsible for the bone marrow fibrosis [22], the most common MPN-associated mutations were retrospectively sought in presentation DNA using an allele-specific PCR approach [23]. No evidence was found of the *JAK2* V617F, *MPL* W515L, or W515 K mutations. The patient commenced nilotinib 300 mg bd with a negligible decrease in *BCR-ABL1* transcripts over the following three months period (Figure 1(a)). He continued to deteriorate clinically, and his final admission was with pyelonephritis due to renal stones. He became increasingly cachectic with worsening splenomegaly and wished to be at home where he died with the cause of death being CML complicated by ischemic heart disease.

3. Discussion

The e19a2 is the most common *BCR-ABL1* variant in CML with patients expressing this transcript type generally considered to respond favourably to TKI therapy. Very few cases of acquired resistance due to *ABL1* KD mutations have been reported in this CML genotype with the Y253H, E355G, T315I, and G250E mutations reported [12–15]. All of these cases achieved significant cytogenetic and/or molecular responses after the introduction of a second generation TKI. This case therefore represents the first description of a Q252H in a patient with e19a2 *BCR-ABL1* CML and who appeared resistant to second generation TKI therapy. Prior to the development of second generation TKIs, the Q252H mutation and further mutations of the ATP phosphate-binding loop (P-loop) of the *ABL1* KD were considered to have a high degree of imatinib resistance and a particularly poor prognosis [24]. However, from subsequent *in vitro* analysis of many *ABL1* KD mutations that has provided a rationale for selection of second generation TKI therapy, the Q252H mutation appears responsive to nilotinib, dasatinib, and bosutinib [25–28]. The

FIGURE 2: Trephine biopsy at BC progression showing (a) significant megakaryocytic hyperplasia and (b) grade II reticulin fibrosis.

lack of response to nilotinib in the case described herein most likely represents the acquisition of further genetic and/or epigenetic events that occur during BC transformation of CML [29].

Also of note is the manifestation of fibrosis associated with the blast crisis. Whereas progressive bone marrow fibrosis is considered an indicator of treatment failure in CML, TKI therapy can reverse fibrosis significantly but does not eliminate its unfavourable prognosis nor guarantee against further fibrotic evolution [30–33]. The fibrosis in this case appeared rapidly in conjunction with progression to blast crisis, a feature previously described in only rare cases [34, 35].

This report describes for the first time, the presence of the Q252H mutation in e19a2 *BCR-ABL1* CML and its association with TKI resistance and progression to BC. The case also serves to highlight the considerable challenges in the treatment of CML BC particularly in the elderly patient with significant comorbidities.

References

- [1] G. Saglio, A. Guerrasio, C. Rosso et al., “New type of Bcr/Abl junction in Philadelphia chromosome—positive chronic myelogenous leukemia,” *Blood*, vol. 76, no. 9, pp. 1819–1824, 1990.
- [2] F. Pane, F. Frigeri, M. Sindona et al., “Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction),” *Blood*, vol. 88, no. 7, pp. 2410–2414, 1996.
- [3] A. Ohsaka, S. Hoshino, M. Kobayashi, H. Kudo, and R. Kawaguchi, “Blast crisis of Philadelphia chromosome-positive chronic myeloid leukaemia carrying micro-bcr breakpoint (e19a2 and e191a),” *British Journal of Haematology*, vol. 118, no. 1, pp. 251–254, 2002.
- [4] J.-J. Lee, H.-J. Kim, Y.-J. Kim et al., “Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts,” *Leukemia*, vol. 18, no. 9, pp. 1539–1540, 2004.
- [5] B. C. Mondal, S. Majumdar, U. B. Dasgupta, U. Chaudhuri, P. Chakrabarti, and S. Bhattacharyya, “e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases,” *Journal of Clinical Pathology*, vol. 59, no. 10, pp. 1102–1103, 2006.
- [6] H. Andrikovics, S. Nahajevszky, A. Szilvási et al., “First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts,” *Hematological Oncology*, vol. 25, no. 3, pp. 143–147, 2007.
- [7] X. Li, J. Yang, X. Chen et al., “A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript,” *Cancer Genetics and Cytogenetics*, vol. 176, no. 2, pp. 166–168, 2007.
- [8] G. Oshikawa, T. Kurosu, A. Arai, N. Murakami, and O. Miura, “Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation,” *Cancer Genetics and Cytogenetics*, vol. 199, no. 1, pp. 56–61, 2010.
- [9] N. P. Shah, “Loss of response to imatinib: mechanisms and management,” *Hematology*, vol. 2005, pp. 183–187, 2005.
- [10] D. Milojkovic and J. F. Apperley, “Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia,” *Clinical Cancer Research*, vol. 15, no. 24, pp. 7519–7527, 2009.
- [11] S. Soverini, A. Hochhaus, F. E. Nicolini et al., “BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet,” *Blood*, vol. 118, no. 5, pp. 1208–1215, 2011.
- [12] C. Popovici, A. Charbonnier, O. Gisserot et al., “Y253H mutation appearing in a μ -BCR-ABL (e19a2) CML,” *Leukemia Research*, vol. 32, no. 2, pp. 361–362, 2008.
- [13] A. Bennour, N. Beaufile, H. Sennana, B. Meddeb, A. Saad, and J. Gabert, “E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib,” *Journal of Clinical Pathology*, vol. 63, no. 8, pp. 737–740, 2010.
- [14] M. Cea, G. Cirmena, A. Garuti et al., “A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib,” *Leukemia Research*, vol. 34, no. 9, pp. e240–e242, 2010.
- [15] S. E. Martin, M. Sausen, A. Joseph, and B. F. Kingham, “Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib,” *Cancer Genetics and Cytogenetics*, vol. 201, no. 2, pp. 133–134, 2010.

- [16] A. Hochhaus, S. G. O'Brien, F. Guilhot et al., "Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia," *Leukemia*, vol. 23, no. 6, pp. 1054–1061, 2009.
- [17] R. Hehlmann, "How I treat CML blast crisis," *Blood*, vol. 120, no. 4, pp. 737–747, 2012.
- [18] J. J. M. van Dongen, E. A. Macintyre, J. A. Gabert et al., "Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia," *Leukemia*, vol. 13, no. 12, pp. 1901–1928, 1999.
- [19] S. E. Langabeer, S. L. McCarron, P. Carroll, J. Kelly, M. O'Dwyer, and E. Conneally, "Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia," *Leukemia Research*, vol. 35, no. 9, pp. e169–e170, 2011.
- [20] S. L. McCarron, L. M. O. Connor, S. E. Langabeer, and E. Conneally, "BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients," *Genetic Testing and Molecular Biomarkers*, vol. 17, no. 2, pp. 170–173, 2013.
- [21] C. Roche-Lestienne and C. Preudhomme, "Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment," *Seminars in Hematology*, vol. 40, no. 2, pp. 80–82, 2003.
- [22] L. Pieri, A. Spolverini, B. Scappini et al., "Concomitant occurrence of BCR-ABL and JAK2V617F mutation," *Blood*, vol. 118, no. 12, pp. 3445–3446, 2011.
- [23] N. McCarthy, S. L. McCarron, and S. E. Langabeer, "Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis," *Acta Haematologica*, vol. 124, no. 3, pp. 160–161, 2010.
- [24] S. Branford, Z. Rudzki, S. Walsh et al., "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis," *Blood*, vol. 102, no. 1, pp. 276–283, 2003.
- [25] T. O'Hare, D. K. Walters, E. P. Stoffregen et al., "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants," *Cancer Research*, vol. 65, no. 11, pp. 4500–4505, 2005.
- [26] M. R. Burgess, B. J. Skaggs, N. P. Shah, F. Y. Lee, and C. L. Sawyers, "Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 9, pp. 3395–3400, 2005.
- [27] H. A. Bradeen, C. A. Eide, T. O'Hare et al., "Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations," *Blood*, vol. 108, no. 7, pp. 2332–2338, 2006.
- [28] S. Redaelli, R. Piazza, R. Rostagno et al., "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants," *Journal of Clinical Oncology*, vol. 27, no. 3, pp. 469–471, 2009.
- [29] D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski, "Chronic myeloid leukemia: Mechanisms of blastic transformation," *Journal of Clinical Investigation*, vol. 120, no. 7, pp. 2254–2264, 2010.
- [30] G. Buesche, R. Hehlmann, H. Hecker et al., "Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia—prospective long-term results from a randomized-controlled trial," *Leukemia*, vol. 17, no. 12, pp. 2444–2453, 2003.
- [31] C. Beham-Schmid, U. Apfelbeck, H. Sill et al., "Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis," *Blood*, vol. 99, no. 1, pp. 381–383, 2002.
- [32] C. E. Bueso-Ramos, J. Cortes, M. Talpaz et al., "Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia," *Cancer*, vol. 101, no. 2, pp. 332–336, 2004.
- [33] G. Buesche, A. Ganser, B. Schlegelberger et al., "Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia," *Leukemia*, vol. 21, no. 12, pp. 2420–2427, 2007.
- [34] Y. Xu, A. E. Wahner, and P. L. Nguyen, "Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate," *Archives of Pathology and Laboratory Medicine*, vol. 128, no. 9, pp. 980–985, 2004.
- [35] J. H. Go and J. Park, "Extramedullary blast crisis of secondary CML accompanying marrow fibrosis," *Korean Journal of Hematology*, vol. 47, no. 4, p. 243, 2012.